On Sep 18, 2019, Keith Kennedy, COO / CFO, exercised options for 22,365 shares in Veracyte (VCYT) for $167,067. Kennedy, subsequent to the transactions...
Bonnie H Anderson, Director and Chairman & CEO, sold 8,000 shares of Veracyte (VCYT) on Sep 10, 2019, for $196,114. Subsequent to the Form 4 filing with...
File did not print ref INSIDERACTIVITY.16 FTMUM 16 CODE FMS Dr Kennedy, following the transactions disclosed in the Form 4 SEC filing, owns 47,449 company...
On Aug 27, 2019, Director, Evan Jones, executed a sale of 10,000 shares in Veracyte (VCYT) for $261,051. Jones has control over 204,653 company shares of...
| Address | 6000 Shoreline Court South San Francisco, California 94080 |
| Phone | +1.650.243.6300 |
| Number of Employees | 270 |
| Recent SEC Filing | 09/20/2019 4 |
| Chairman & Chief Executive Officer | Bonnie H. Anderson |
| Chief Operating & Financial Officer | Keith Kennedy |
| Chief Scientific & Medical Officer | Giulia C. Kennedy |
| Chief Information Officer | Ashish Kheterpal |
| Price Open | $26.02 |
| Previous Close | $26.05 |
| 52 Week Range | $8.77 - 31.18 |
| Market Capitalization | $1.3 B |
| Shares Outstanding | 48.4 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 11/04/2019 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$0.29 |
| Beta vs. S&P 500 | N/A |
| Revenue | $92.0 M |
| Net Profit Margin | -11.01% |
| Return on Equity | -10.26% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
